A61P 25/18
Antipsychotics, i.e. neuroleptics
Official title: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
A61P25/18 (Antipsychotics, i.e. neuroleptics) appears on 10,855 US grants and 15,500 published applications in this corpus.
Search patents in A61P- Granted patents
- 10,855
- Published applications
- 15,500
- Assignees
- 3,299
- Inventors
- 21,797
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 9 | 0 |
| 1978 | 8 | 0 |
| 1979 | 12 | 0 |
| 1980 | 5 | 0 |
| 1981 | 20 | 0 |
| 1982 | 13 | 0 |
| 1983 | 14 | 0 |
| 1984 | 21 | 0 |
| 1985 | 16 | 0 |
| 1986 | 21 | 0 |
| 1987 | 17 | 0 |
| 1988 | 26 | 0 |
| 1989 | 47 | 0 |
| 1990 | 44 | 0 |
| 1991 | 64 | 0 |
| 1992 | 63 | 0 |
| 1993 | 66 | 0 |
| 1994 | 71 | 0 |
| 1995 | 67 | 0 |
| 1996 | 106 | 0 |
| 1997 | 159 | 0 |
| 1998 | 139 | 0 |
| 1999 | 136 | 0 |
| 2000 | 139 | 0 |
| 2001 | 190 | 58 |
| 2002 | 242 | 353 |
| 2003 | 256 | 580 |
| 2004 | 241 | 737 |
| 2005 | 229 | 742 |
| 2006 | 342 | 775 |
| 2007 | 353 | 819 |
| 2008 | 373 | 947 |
| 2009 | 420 | 1019 |
| 2010 | 548 | 1232 |
| 2011 | 570 | 1015 |
| 2012 | 688 | 950 |
| 2013 | 694 | 700 |
| 2014 | 663 | 707 |
| 2015 | 574 | 657 |
| 2016 | 493 | 588 |
| 2017 | 532 | 597 |
| 2018 | 433 | 516 |
| 2019 | 359 | 489 |
| 2020 | 308 | 416 |
| 2021 | 290 | 343 |
| 2022 | 217 | 291 |
| 2023 | 151 | 286 |
| 2024 | 176 | 302 |
| 2025 | 152 | 243 |
| 2026 | 77 | 138 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Salt containing piperazine polycyclic derivative, crystal form thereof, preparation method therefor, and use thereof6 Oct 2026US 12,753,166 B2Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- Long acting injectable formulation comprising risperidone and biodegradable polymers29 Sep 2026US 12,746,197 B2Medincell
- Heterocyclic substituted fused γ-carboline derivative, preparation method therefor, intermediate thereof and use thereof1 Sep 2026US 12,723,044 B2Jiangsu Nhwa Pharmaceutical Co., Ltd
- Salts of neuroceuticals and uses thereof25 Aug 2026US 12,714,711 B2SyneuRx International (Taiwan) Corp.
- Formulations of psilocybin and psilocin compounds as serotonin agonists in combination with 3,4 methylenedioxymethamphetamine (MDMA)18 Aug 2026US 12,708,635 B2Altrartis Therapeutics Inc.
- Oxysterols and methods of use thereof8 Oct 2026US 2026/0308197 A1Sage Therapeutics, Inc.
- Cannabidiol preparations and its uses1 Oct 2026US 2026/0294937 A1Jazz Pharmaceuticals Research UK Limited
- Novel dioxane derivatives1 Oct 2026US 2026/0297067 A1Boehringer Ingelheim International GmbH
- Modulation of Dystrophia Myotonica-Protein Kinase (DMPK) Expression1 Oct 2026US 2026/0297587 A1Ionis Pharmaceuticals, Inc.
- Heteroaromatic compounds for the treatment of neurological disorders24 Sep 2026US 2026/0285865 A1Suven Life Sciences Limited
Most cited
By later US patents
- Gum pad for delivery of medication to mucosal tissues1,140US 6,319,510 B12001
- Method and apparatus for automatically configuring a system based on a user's monitored system interaction and preferred system access times926US 5,977,964 AIntel Corporation · 1999
- Process for preparing diaminophenothiazinium compounds687US 8,765,942 B2Provence Technologies · 2014
- P38 inhibitors and methods of use thereof444US 7,799,782 B2Array BioPharma Inc. · 2010
- Dual variable domain immunoglobulin and uses thereof391US 7,612,181 B2Abbott Laboratories · 2009